| SMO | Smoothened |
| HH | Hedgehog |
| mTOR-Akt | Mammalian target of rapamycin-protein kinase B |
| PKA | Protein kinase A |
| SUFU | Suppressor on fused homolog |
| GPCR | G-protein-coupled receptor |
| EMT | Epithelial–mesenchymal transition |
| MMPs | Matrix metalloproteinases |
| FoxF1 | Forkhead box F1 |
| BMP4 | Morphogenic protein 4 |
| PI3K | Phosphoinositide 3-kinase |
| CRD | Cysteine rich domain |
| Gi | G inhibitory |
| GEFs | Guanine exchange factors |
| GTP | Guanosine-5′-triphosphate |
| GDP | Guanosine diphosphate |
| GAPs | GTPase-activating proteins |
| PLCγ | Phospholipase C gamma |
| HR | Hormone receptor |
| HER2 | Human epidermal growth factor receptor 2 |
| TNBC | Triple negative breast cancer |
| ER | Estrogen receptor |
| PR | Progesterone receptor |
| DCIS | Ductal carcinoma in situ |
| IBC | Invasive breast cancer |
| Cyr61 | Cysteine-rich angiogenic inducer 61 |
| VEGFR2 | Vascular endothelial growth receptor 2 |
| CA | Carbonic anhydrase |
| CAFs | Cancer-associated fibroblasts |
| CDKs | Cyclin-dependent kinases |
| LT | Liver transplantation |
| HBx | HBV gene product HBx protein |
| CDK1 | Cyclin-dependent kinase 1 |
| CHSY1 | Chondroitin sulfate synthase 1 |
| PDAC | Pancreatic ductal adenocarcinoma |
| TGF-α | Transforming growth factor-alpha |
| FDA | Food and Drug Administration |
| FOLFOX | Folinic acid, Fluorouracil, Oxaliplatin |
| FOLFIRI | Folinic acid, 5-FU, IRInotecan |
| AMC | Acute myelogenous leukemia |
| CSC | Cancer stem cell |
| hMSCs | Human mesenchymal stem cells |